SCHEMBL29615512

SCHEMBL29615512

NC(=O)CC[C@H](N)C(=O)N1CCCC[C@H]1C(=O)O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACE P12821 7/20 0.52
REN P00797 3/20 0.52
DPP7 Q9UHL4 3/20 0.49
DPP4 P27487 1/20 0.49
FAP Q12884 1/20 0.49
DPP8 Q6V1X1 1/20 0.49
DPP9 Q86TI2 1/20 0.49
KDM4E B2RXH2 1/20 0.47
F2 P00734 1/20 0.47
LMNA P02545 1/20 0.47
LTA4H P09960 1/20 0.47
MAPT P10636 1/20 0.47
PEPD P12955 1/20 0.47
ALOX15 P16050 1/20 0.47
PTGS1 P23219 1/20 0.47
HTR2A P28223 1/20 0.47
PTGS2 P35354 1/20 0.47
HRH1 P35367 1/20 0.47
THPO P40225 1/20 0.47
PMP22 Q01453 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5970700 0.96 ACE (0.57) ACERENDPP7DPP4FAP
SCHEMBL5970696 0.96 ACE (0.57) ACERENDPP7DPP4FAP
SCHEMBL15528751 0.92 ACE (0.53) ACERENDPP7DPP4FAP
SCHEMBL7271779 0.91 ACE (0.52) ACERENDPP7DPP4FAP
SCHEMBL29630367 0.91 ACE (0.52) ACERENDPP7DPP4FAP
SCHEMBL10779357 0.85 ACE (0.71) ACERENDPP7DPP4FAP
SCHEMBL30052872 0.85 ACE (0.71) ACERENDPP7DPP4FAP
SCHEMBL10779361 0.85 ACE (0.71) ACERENDPP7DPP4FAP
SCHEMBL28827157 0.85 ACE (0.71) ACERENDPP7DPP4FAP
SCHEMBL2244479 0.83 ACE (0.48) ACERENKDM4EF2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260146063-A1 CYCLIC CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF OHIO STATE INNOVATION FOUNDATION (US) 2026-05-28 US disclosed
US-20260125426-A1 CYCLIC CELL-PENETRATING PEPTIDES AND USES THEREOF OHIO STATE INNOVATION FOUNDATION (US) 2026-05-07 US disclosed
US-20260070947-A1 CYCLIC CELL-PENETRATING PEPTIDE COMPOUNDS OHIO STATE INNOVATION FOUNDATION (US) 2026-03-12 US disclosed
US-20260070948-A1 CYCLIC CELL-PENETRATING PEPTIDES WITH CARGO OHIO STATE INNOVATION FOUNDATION (US) 2026-03-12 US disclosed
US-20260008812-A1 CELL-PENETRATING PEPTIDE COMPOUNDS OHIO STATE INNOVATION FOUNDATION (US) 2026-01-08 US disclosed
US-20260008816-A1 CYCLIC CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF OHIO STATE INNOVATION FOUNDATION (US) 2026-01-08 US disclosed
US-20260008813-A1 CELL-PENETRATING PEPTIDE COMPOUNDS OHIO STATE INNOVATION FOUNDATION (US) 2026-01-08 US disclosed
US-20260001916-A1 CYCLIC CELL-PENETRATING PEPTIDE COMPOUNDS OHIO STATE INNOVATION FOUNDATION (US) 2026-01-01 US disclosed
US-12454552-B2 Cyclic cell penetrating peptides comprising beta-hairpin motifs and methods of making and using thereof OHIO STATE INNOVATION FOUNDATION (US) 2025-10-28 US disclosed
US-20250243244-A1 CYCLIC CELL PENETRATING PEPTIDES ENTRADA THERAPEUTICS, INC. 2025-07-31 US disclosed
US-20240360174-A1 CELL-PENETRATING PEPTIDE SEQUENCES OHIO STATE INNOVATION FOUNDATION 2024-10-31 US disclosed
US-20240358845-A1 COMPOSITIONS AND METHODS FOR INTRACELLULAR THERAPEUTICS ENTRADA THERAPEUTICS, INC. 2024-10-31 US disclosed
US-20240245790-A1 CYCLIC CELL PENETRATING PEPTIDES ENTRADA THERAPEUTICS, INC. 2024-07-25 US disclosed
US-11987647-B2 Cyclic cell-penetrating peptides with one or more hydrophobic residues OHIO STATE INNOVATION FOUNDATION (US) 2024-05-21 US disclosed
US-20240158445-A1 CYCLIC CELL-PENETRATING PEPTIDES WITH THREE OR MORE HYDROPHOBIC RESIDUES NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2024-05-16 US disclosed
US-11878046-B2 Di-sulfide containing cell penetrating peptides and methods of making and using thereof OHIO STATE INNOVATION FOUNDATION (US) 2024-01-23 US disclosed
US-20220306693-A1 CYCLIC CELL PENETRATING PEPTIDES COMPRISING BETA-HAIRPIN MOTIFS AND METHODS OF MAKING AND USING THEREOF OHIO STATE INNOVATION FOUNDATION 2022-09-29 US disclosed
US-20220177523-A1 CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF ENTRADA THERAPEUTICS, INC. 2022-06-09 US disclosed
US-11351222-B2 Di-sulfide containing cell penetrating peptides and methods of making and using thereof OHIO STATE INNOVATION FOUNDATION (US) 2022-06-07 US disclosed
US-20220160819-A1 DI-SULFIDE CONTAINING CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2022-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (20 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260008816-A1 CYCLIC CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF SLC3A2, SPPL2B, SLC7A1 ACE 3419/4885REN 3017/4885DPP7 171/4885
US-11878046-B2 Di-sulfide containing cell penetrating peptides and methods of making and using thereof IKBKE, IKBKB, SHARPIN ACE 4573/4885REN 4648/4885DPP7 846/4885
US-20250243244-A1 CYCLIC CELL PENETRATING PEPTIDES SLC47A1, SLC47A2, VIP ACE 4080/4885REN 3750/4885DPP7 393/4885
US-20240245790-A1 CYCLIC CELL PENETRATING PEPTIDES SLC47A1, SLC47A2, VIP ACE 4080/4885REN 3750/4885DPP7 393/4885
US-20260008812-A1 CELL-PENETRATING PEPTIDE COMPOUNDS SLC38A7, SLC7A1, SLC6A7 ACE 1939/4885REN 1257/4885DPP7 304/4885
US-20260146063-A1 CYCLIC CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF VIP, SLC7A1, SLC6A15 ACE 1946/4885REN 1662/4885DPP7 759/4885
US-20220306693-A1 CYCLIC CELL PENETRATING PEPTIDES COMPRISING BETA-HAIRPIN MOTIFS AND METHODS OF MAKING AND USING THEREOF CHN2, TAP2, VIP ACE 3325/4885REN 2618/4885DPP7 325/4885
US-20260125426-A1 CYCLIC CELL-PENETRATING PEPTIDES AND USES THEREOF SLC7A1, TAP1, SLC7A5 ACE 3598/4885REN 4125/4885DPP7 944/4885
US-20220177523-A1 CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF VIP, LNPEP, TAP1 ACE 3899/4885REN 3405/4885DPP7 306/4885
US-20260070947-A1 CYCLIC CELL-PENETRATING PEPTIDE COMPOUNDS SLC7A1, SLC38A7, SLC6A19 ACE 2843/4885REN 2030/4885DPP7 819/4885
US-20240358845-A1 COMPOSITIONS AND METHODS FOR INTRACELLULAR THERAPEUTICS VIP, CHERP, NFATC1 ACE 3996/4885REN 3379/4885DPP7 1376/4885
US-20220160819-A1 DI-SULFIDE CONTAINING CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF IKBKE, IKBKB, SHARPIN ACE 4573/4885REN 4648/4885DPP7 846/4885
US-20260070948-A1 CYCLIC CELL-PENETRATING PEPTIDES WITH CARGO SLC7A1, SLC38A7, SLC6A19 ACE 2988/4885REN 2481/4885DPP7 891/4885
US-11351222-B2 Di-sulfide containing cell penetrating peptides and methods of making and using thereof IKBKE, IKBKB, SHARPIN ACE 4573/4885REN 4648/4885DPP7 846/4885
US-20260001916-A1 CYCLIC CELL-PENETRATING PEPTIDE COMPOUNDS SLC7A1, SLC38A7, SLC6A19 ACE 2236/4885REN 2364/4885DPP7 426/4885
US-12454552-B2 Cyclic cell penetrating peptides comprising beta-hairpin motifs and methods of making and using thereof CHN2, TAP2, VIP ACE 3325/4885REN 2618/4885DPP7 325/4885
US-20260008813-A1 CELL-PENETRATING PEPTIDE COMPOUNDS SLC7A1, SLC38A7, SLC6A19 ACE 2506/4885REN 1284/4885DPP7 654/4885
US-20240158445-A1 CYCLIC CELL-PENETRATING PEPTIDES WITH THREE OR MORE HYDROPHOBIC RESIDUES SLC3A2, SLC7A1, ARGLU1 ACE 4661/4885REN 4059/4885DPP7 979/4885
US-20240360174-A1 CELL-PENETRATING PEPTIDE SEQUENCES VIP, LNPEP, NGLY1 ACE 3539/4885REN 3492/4885DPP7 235/4885
US-11987647-B2 Cyclic cell-penetrating peptides with one or more hydrophobic residues VIP, LNPEP, TAP1 ACE 4059/4885REN 4229/4885DPP7 339/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.